integrin subunit beta 2
Sign in to saveAlso known as leukocyte cell adhesion molecule CD18, leukocyte-associated antigens CD18/11A, CD18/11B, CD18/11C, ITGB2, integrin beta chain, beta 2, Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta, integrin, beta 2 (complement component 3 receptor 3 and 4 subunit), complement component 3 receptor 3 and 4 subunit, cell surface adhesion glycoprotein (LFA-1/CR3/P150,959 beta subunit precursor)
mammalian protein found in Homo sapiens
Protein · UniProt
Integrin beta-2
- Gene
- ITGB2
- Organism
- Homo sapiens (Human)
- Length
- 769 aa
- Molecular mass
- 84,791 Da
- Evidence
- 1: Evidence at protein level
Integrin ITGAL:ITGB2 is a receptor for ICAM1, ICAM2 and ICAM3 (PubMed:1676048, PubMed:23775590, PubMed:38195629). Integrin ITGAL:ITGB2 is also a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL (PubMed:29100055). Integrins ITGAM:ITGB2 and ITGAX:ITGB2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin ITGAX:ITGB2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin ITGAM:ITGB2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin ITGAM:ITGB2 is also a receptor for fact…
Swiss-Prot (reviewed) · via UniProt
Research
2,291 papers- Intracellular β(2) integrin (CD11/CD18) interacting partners in neutrophil trafficking.European journal of clinical investigation · 2018
- Interactions via α(2)β(1) Cell Integrin May Protect against the Progression of Airway Structural Changes in Asthma.International journal of molecular sciences · 2021
- beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells.Cancer research · 2009
- Endothelial cells use alpha 2 beta 1 integrin as a laminin receptor.The Journal of cell biology · 1989
- Cloning and expression of a divergent integrin subunit beta 8.The Journal of biological chemistry · 1991
via PubMed
Clinical Trials
3 registered- ACTIVE_NOT_RECRUITINGLong-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)Rocket Pharmaceuticals Inc. · NCT06282432
- PHASE1WITHDRAWNA Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-IRocket Pharmaceuticals Inc. · NCT03825783
- PHASE1/PHASE2COMPLETEDA Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-IRocket Pharmaceuticals Inc. · NCT03812263